Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives

Página do item simplificado
dc.citation.volume8
dc.contributor.authorMachado, Daisy Maria [UNIFESP]
dc.contributor.authorMachado de Sant'Anna Carvalho, Alexandre
dc.contributor.authorRiera, Rachel [UNIFESP]
dc.coverageAlbany
dc.date.accessioned2020-07-17T14:03:29Z
dc.date.available2020-07-17T14:03:29Z
dc.date.issued2017
dc.description.abstractAdolescents are a critical population that is disproportionately impacted by the HIV epidemic. More than 2 million adolescents between the age group of 10 and 19 years are living with HIV, and millions are at risk of infection. HIV risks are considerably higher among girls, especially in high-prevalence settings such as eastern and southern Africa. In addition to girls, there are other vulnerable adolescent subgroups, such as teenagers, who use intravenous (IV) drugs, gay and bisexual boys, transgender youth, male sex workers, and people who fall into more than one of these categories. Pre-exposure prophylaxis (PrEP) is a new intervention for people at high risk for acquiring HIV, with an estimated HIV incidence of > 3%. Recent data from trials show evidence of the efficacy of PrEP as a powerful HIV prevention tool in high-risk populations, including men who have sex with men, HIV-1-serodiscordant heterosexual couples, and IV drug users. The reported efficacy in those trials of the daily use of oral tenofovir, alone or in combination with emtricitabine, to prevent HIV infection ranged from 44% to 75% and was heavily dependent on adherence. Despite the proven efficacy of PrEP in adult trials, concerns remain about its feasibility in real-life scenarios due to stigma, cost, and limited clinician experience with PrEP delivery. Recent studies are attempting to expand the inquiry into the efficacy of such HIV prophylaxis approaches in adolescent populations, but there are still many gaps in knowledge, and no country has yet approved it for use with adolescents. The aim of this review was to identify and summarize the evidence from studies on PrEP for adolescents. We have compiled and reviewed published studies focusing on safety, feasibility, adherence to therapeutics, self-perception, and legal issues related to PrEP in people aged between 10 and 24 years.en
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Pediat, Disciplina Infectol Pediat, Rua Pedro de Toledo 928, BR-04039002 Sao Paulo, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Rio De Janeiro, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Med, Disciplina Med Baseada Evidencias, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Pediat, Disciplina Infectol Pediat, Rua Pedro de Toledo 928, BR-04039002 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Med, Disciplina Med Baseada Evidencias, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent137-148
dc.identifierhttp://dx.doi.org/10.2147/AHMT.S112757
dc.identifier.citationAdolescent Health Medicine And Therapeutics. Albany, v. 8, p. 137-148, 2017.
dc.identifier.doi10.2147/AHMT.S112757
dc.identifier.fileWOS000416489000001.pdf
dc.identifier.issn1179-318X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55428
dc.identifier.wosWOS:000416489000001
dc.language.isoeng
dc.publisherDove Medical Press Ltd
dc.relation.ispartofAdolescent Health Medicine And Therapeutics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHIV preventionen
dc.subjectpre-exposure prophylaxis (PrEP)en
dc.subjectadolescentsen
dc.subjectyouthen
dc.titleAdolescent pre-exposure prophylaxis for HIV prevention: current perspectivesen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000416489000001.pdf
Tamanho:
573.45 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos